anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine formula for treating poultry muscular stomach and glandular stomach inflammation and a preparation method thereof. The formula is composed of the following traditional Chinese herbals in parts by weight: 21 to 25 parts of rhizoma atractylodis, 16 to 20 parts of bighead atractylodes rhizome, 10 to 14 parts of banksia rose, 10 to 14 parts of green tangerine peel, 10 to 14 parts of villous amomum fruit, 13 to 17 parts of bletilla striata, 7 to 11 parts of licorice, 16 to 20 parts of cuttlebone, 16 to 20 parts of concha arcae, 16 to 20 parts of limonite, 16 to 20 parts of oyster, 10 to 14 parts of poria cocos, and 13 to 17 parts of dandelion. The formula can be made into powder. The rhizoma atractylodis is acrid and aromatic, has the functions of dispelling evil, drying dampness, invigorating the stomach, and repelling foulness, and is assisted by the following components: bighead atractylodes rhizome having functions of boosting qi and invigorating spleen, banksia rose having functions of moving qi and relieving pains, green tangerine peel having functions of breaking qi and removing food retention, villous amomum fruit having functions of invigorating stomach and promoting digestion, cuttlebone, concha arcae, limonite, oyster, wherein cuttlebone, concha arcae, limonite, and oyster have the functions of producing acid and eliminating swelling; bletilla striata having functions of stopping bleeding and promoting tissue generation, poria cocos, and dandelion, wherein poria cocos and dandelion have the function of inducing diuresis to alleviate edema. The traditional Chinese medicine formula can treat the poultry muscular stomach and glandular stomach inflammation, at the same time can promote the regular operations of blood, qi, and fluids in poultry body, brings the metabolism of poultry to a normal state, and thus treats both the root and symptoms. After healing, the poultry has a good appetite, the growth is good, and relapse is difficult.
Behaviour problems, i.e. symptoms of oppositional defiant disorder (ODD) and conduct disorder (CD) are among the prevalent psychiatric disorders in children and one of the leading causes of help-seeking for mental health problems in children. There are several efficacious treatments for such problems in young children. However, most of these require that parents meet in groups. This is not always feasible. It is therefore a need to develop treatments that can deal with parents and families individually. Parent-Child Interaction Therapy (PCIT) is such an individually based treatment. Efficacy studies indicate symptom reduction greater that in treatment as usual (TAU). However, there is a need to study its effectiveness in ordinary clinical practise. This trial will study its effect in ordinary psychiatric clinics in the middle of Norway and compare it to the regular treatment (TAU) provided to young children with behavior problems in these clinics.
STUDY DESIGN: A retrospective cohort study.
OBJECTIVE: This study aimed to assess postoperative sclerotic modic changes (MCs) following transforaminal lumbar interbody fusion for lumbar degenerative disc disease, investigating their prevalence, risk factors, and association with clinical outcomes.
SUMMARY OF BACKGROUND DATA: Sclerotic MCs may occur in patients with lumbar degenerative disc disease after lumbar interbody fusion. The incidence and characteristics of postoperative sclerotic MCs, as well as their clinical impact, are unknown.
MATERIALS AND METHODS: The study included 467 patients (510 levels) who underwent single or two-level transforaminal lumbar interbody fusion surgery, divided into a postoperative sclerotic MC group (60 patients, 66 levels) and a non-MC group (407 patients, 444 levels). The time of development and location of postoperative sclerotic MCs, fusion rate, cage subsidence, bilateral process decompression, and cross-link usage were recorded. Preoperative, postoperative, and follow-up visual analogue scale and Oswestry disability index scores were collected. Multivariable logistic regression was used to evaluate factors associated with the development of postoperative sclerotic MCs.
RESULTS: The prevalence of postoperative sclerotic MCs was 12.8%. The postoperative sclerotic MC group had a higher body mass index (BMI). The postoperative sclerotic MC group demonstrated a fusion rate of 47%, significantly lower than that of the non-MC group (71%) at six months post-operation. At final follow-up, the fusion rate in the postoperative sclerotic MC group was 62%, significantly lower than that of the non-MC group (86%). Postoperative visual analogue scale and Oswestry disability index scores were significantly higher in the group with postoperative sclerotic MCs. BMI and osteoporosis were significantly associated with the development of postoperative sclerotic MCs.
CONCLUSION: Postoperative sclerotic MCs generally appear within the first year after surgery, with a prevalence of 12.8%. The presence of postoperative sclerotic MCs can adversely impact postoperative outcomes. To prevent postoperative sclerotic MCs, the authors postulate extending the immobilization period with external bracing and improving the management of BMI and osteoporosis in the perioperative time window.
Study design This is a phase II, open-label, single-arm tissue and plasma acquisition study assessing the efficacy, safety and underlying resistance mechanisms of osimertinib (80 mg orally, once daily) as first-line treatment in patients with locally advanced or metastatic EGFR mutation positive non-small cell lung cancer who are EGFR tyrosine kinase inhibitor treatment-naïve and eligible for first-line treatment. Participants with EGFR mutation-positive non-small cell lung cancer will be required to consent to 2 mandatory tumour biopsies to be considered for enrolment in this study. The first biopsy will be done prior to initiating treatment with osimertinib and the second biopsy will be obtained any time between Investigator assessed, Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1)-defined progression and before the start of any new anticancer treatment. A third optional biopsy may be taken during the course of treatment at the Investigator's discretion if the patient consents and if clinically feasible. Tumour tissue and plasma samples will be collected and examined for genetic and non genetic aberrations that may be important in determining response and resistance to the treatment that participants will receive as a part of their cancer care. Patients should continue on osimertinib until progression or until other treatment discontinuation criteria are met. However, if patients continue to show clinical benefit to treatment as judged by the Investigator, patients may continue to receive osimertinib beyond RECIST 1.1-defined progression. Therefore, there is no maximum duration of treatment. Tumour assessments will be performed at baseline and then every 8 weeks from study enrolment until 3.5 years, and then every 10 weeks until RECIST 1.1-defined. Patients will be followed up for a period of 28 days following discontinuation of osimertinib. Target patient population Male and female patients aged 18 years and over with locally advanced or metastatic pathologically confirmed adenocarcinoma of the lung, not amenable to curative surgery or radiotherapy. Patients will have a tumour that harbours one of the EGFR mutations known to be associated with EGFR tyrosine kinase inhibitor sensitivity, either alone or in combination with other EGFR mutations (EGFR mutation status determined by a local laboratory). Patients must be EGFR tyrosine kinase inhibitor treatment-naïve and eligible to receive first line treatment with osimertinib. Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer with a significant selectivity margin over wild type EGFR. Osimertinib (80 mg orally, once daily) will be administered. Doses may be reduced to 40 mg if needed.
The invention discloses a method for producing a red blood cell drug containing L-ASPase II (L-asparaginase) by in vitro induction. The method comprises the steps of: 1) using a lentiviral vector system to transform induced pluripotent stem (IPS) cells: I. constructing a pLenti6.3/V5-GW/Em-GFP VerA-L-ASPase II plasmid; II. using 293T cells to perform packaging so as to generate high titer virus particles containing L-ASPase II; III. using the virus particles to transfect induced pluripotent stem cells; and 2) inducing the induced pluripotent stem cells in vitro to generate L-ASPase II-containing red blood cells: I. subjecting IPS cells to in vitro differentiation induction to form an erythroid body EB; and II. performing induced differentiation on EB to obtain mature red cells. The method provided in the invention performs genetic modification on IPS cells by the lentiviral vector system, and induces them in vitro to generate red blood cells containing L-ASPase II. The generated red blood cells can be used as a sustained release carrier of L-ASPase II, and also can maintain the original shapes and functions of red blood cells. The toxic and side effects of L-ASPase II are further reduced, so that the method lays a solid foundation for future clinical application.
NEW MATERIAL:A polypeptide which is a functional unit of caldesmon and expressed by formula I [R is Ala-X (X is polypeptide residue expressed by formula II), H-X or H]. USE:A treating agent for cancer. PREPARATION:For example, the whole RNA is extracted from an avian germinal gizzard smooth muscle according to a conventional method and mRNA is then isolated by oligo(dT)cellulose column chromatography. The resultant mRNA is used as a template to prepare a cDNA with a reverse transpcriptase and construct a cDNA library. The obtained library is screened with Escherichia coli to select a clone containing a gene coding the polypeptide expressed by formula I. The obtained gene is separated, treated with a restriction enzyme and linked to a vector, etc., to prepare a recombinant plasmid, which is then introduced into a host and carry out transformation. The resultant transformant is subsequently cultured to afford the polypeptide expressed by formula I.
Ado-trastuzumab emtansine is a HER2-targeted antibody-drug conjugate. The antibody is the humanized anti-HER2 IgG1, trastuzumab. The small molecule cytotoxin, DM1, is a microtubule inhibitor. Upon binding to sub-domain IV of the HER2 receptor, ado-trastuzumab emtansine undergoes receptor-mediated internalization and subsequent lysosomal degradation, resulting in intracellular release of DM1-containing cytotoxic catabolites. Binding of DM1 to tubulin disrupts microtubule networks in the cell, which results in cell cycle arrest and apoptotic cell death. In addition, in vitro studies have shown that similar to trastuzumab, ado-trastuzumab emtansine inhibits HER2 receptor signaling, mediates antibody-dependent cell-mediated cytotoxicity and inhibits shedding of the HER2 extracellular domain in human breast cancer cells that overexpress HER2.
PURPOSE: This study aims to evaluate the role of intraoperative control of the watertightness of vesicourethral anastomosis extravasation control (VUAEC) in predicting vesicourethral anastomosis (VUA) healing and early postoperative outcomes in patients undergoing robot-assisted radical prostatectomy (RARP).
METHODS: 100 patients who underwent RARP between October 2020 and May 2023 were consecutively included in the study. Preoperatively, the patients were randomized to undergo VUAEC (Group-A) or not (Group-B). Patients in Group-A were evaluated in 2 subgroups: those with no extravasation observed during VUAEC (Group-A1; n = 31 (62%)) and those with extravasation (Group-A2; n = 19 (38%)). On the 8th post-operative day, a gravity cystogram (GC) was performed on all patients to assess VUA healing.
RESULTS: There was no statistically significant difference between the groups in terms of clinical features, drain removal time, length of hospital stay, extravasation on GC, catheter removal time and postoperative complications (p > 0.05, for each). There was also no statistically significant difference between the subgroups in terms of drain removal time, length of hospital stays, catheter removal time (p > 0.05, for each). In Group-A2, urinary extravasation on GC was found in a greater percentage, but the difference remained statistically insignificant (p = 0.082).
CONCLUSIONS: Performing intraoperative VUAEC did not have a significant role in the prediction of VUA healing and early postoperative outcomes in patients undergoing RARP. The current study did not identify a substantial clinical benefit of routine intraoperative VUAEC.
FIELD: veterinary. SUBSTANCE: method involves addition of sodium succinate to the diet of mice at the diurnal dose 0.5-1 mmole/kg. After 30-31 days of preparation intake mice body mass is increased by 5-21%, index of thymus and spleen mass is increased by 19-82 and 42-47%, and DNA content in femoral bone marrow bone - by 10-34%. These inducible changes are stable for at least 15 days after cessation of preparation feeding to animals and their X-ray irradiation at the dose 3 Gr. EFFECT: increased effectiveness of agent proposed. 1 dwg, 3 tbl
PURPOSE:To dissociate an antibody with a high dissociation ability, by mixing a sample blood with a specific dissociating solution in blood transfusion, subjecting the resultant mixture solution to centrifugal separating operation to separate layers, and taking out only the antibody layer, floating on the topmost layer, and dissolved therein. CONSTITUTION:A given amount of blood is taken from a collected blood, and an antibody is dissociated from erythrocytes therein. In the process, the sample blood is mixed with physiological saline solution and a dissociating solution consisting of trichlorotrifluoroethane and methylene chloride (a mixture of the former with the latter at 95-20:5-80, preferably 30:70 ratio) are in equivalent volumes, and the resultant mixture solution is then subjected to centrifugal separating operation (under conditions of 30-40 deg.C temperature, 2,500-3,500r.p.m. for 3-7min) to separate layers. Only the antibody layer, floating on the topmost layer, and dissolved therein is taken out to separate the antibody from erythrocytes. According to this method, a very high dilution ratio can be obtained in separating the antibody, and the dissociating operation can be rapidly carried out while removing chronic poisoning of operators by organic solvents.
Provided is a P4 peptide, which contains functional epitopes of the PsaA  protein of Streptococcus pneumoniae, and related methods and compositions. A  peptide that comprises the amino acid sequence defined in SEQ ID NO:1 (an example of the P4 peptide) is provided. Also provided is a peptide comprising the amino acid sequence defined as VPSLFVDSSVDDRPMKTVSQDTNIPIYAQIFTDS (SEQ ID  NO:2). P4 peptide mimetics having a conformational structure identical or similar to the conformation of P4 (e.g., SEQ ID NO: 1 and SEQ ID NO:2) are provided. An antibody that specifically binds to the epitope defined by the disclosed peptides is provided. For example, the antibody can specifically bind to a peptide comprising the sequence set forth in SEQ ID NO: 1 and having the conformation defined by the peptide consisting of SEQ ID NO: 1. An antibody that specifically binds to a peptide comprising the sequence set forth in SEQ ID NO:2 and having the conformation defined by the peptide consisting of SEQ ID NO:2 is also provided. A P4-specific antibody is PsaA-specific since P4 defines an epitope specific for PsaA. A vaccine comprising the peptide of SEQ ID NO: 1 and a pharmaceutical carrier is provided. A  vaccine comprising a peptide of SEQ ID NO:2 and a pharmaceutical carrier is also provided. Methods of using the peptides and antibodies of the invention are provided. Diagnostic kits comprising a P4 peptide is also provided.
AIMS: Physiological activation of the heart using algorithms to minimize right ventricular pacing (RVPm) may be an effective strategy to reduce adverse events in patients requiring anti-bradycardia therapies. This systematic review and meta-analysis aimed to evaluate current evidence on clinical outcomes for patients treated with RVPm algorithms compared to dual-chamber pacing (DDD).
METHODS AND RESULTS: We conducted a systematic search of the PubMed database. The predefined endpoints were the occurrence of persistent/permanent atrial fibrillation (PerAF), cardiovascular (CV) hospitalization, all-cause death, and adverse symptoms. We also aimed to explore the differential effects of algorithms in studies enrolling a high percentage of atrioventricular block (AVB) patients. Eight studies (7229 patients) were included in the analysis. Compared to DDD pacing, patients using RVPm algorithms showed a lower risk of PerAF [odds ratio (OR) 0.74, 95% confidence interval (CI) 0.57-0.97] and CV hospitalization (OR 0.77, 95% CI 0.61-0.97). No significant difference was found for all-cause death (OR 1.01, 95% CI 0.78-1.30) or adverse symptoms (OR 1.03, 95% CI 0.81-1.29). No significant interaction was found between the use of the RVPm strategy and studies enrolling a high percentage of AVB patients. The pooled mean RVP percentage for RVPm algorithms was 7.96% (95% CI 3.13-20.25), as compared with 45.11% (95% CI 26.64-76.38) of DDD pacing.
CONCLUSION: Algorithms for RVPm may be effective in reducing the risk of PerAF and CV hospitalization in patients requiring anti-bradycardia therapies, without an increased risk of adverse symptoms. These results are also consistent for studies enrolling a high percentage of AVB patients.
INTRODUCTION: Congenital Central Hypoventilation Syndrome (CCHS) is a rare disease due to a severely impaired central control of breathing and dysfunction of the autonomic nervous system. Ophthalmologic abnormalities are common in patients with CCHS and include horizontal strabismus, pupil and iris abnormalities and ptosis. We report a unique case of CCHS in association with monocular elevation deficit (MED) in a boy diagnosed with CCHS at birth.
CASE DESCRIPTION: We report a case of a boy with a confirmed diagnosis of CCHS (complete sequencing of the paired-like homeobox 2b (PHOX2B) gene) after presenting little respiratory effort and cyanosis at birth. The ophthalmological examination shows an impaired elevation of the left eye, both in adduction and abduction, associated with mild and variable left ptosis. His mother has observed that the left eyelid elevates when the child feeds. A deviation in the primary gaze position or a chin-up position are not present. The funduscopic examination is normal. Given that deviation is limited to upgaze, the ptosis is mild and the patient's age, observation is decided.
CONCLUSIONS: Ophthalmologic abnormalities are common in patients with CCHS and include horizontal strabismus, pupil and iris abnormalities and ptosis. To the best of our knowledge, this is the first report of MED in association with CCHS. Further studies are needed to determine if an association between MED and CCHS exists or is just a casual finding in this case.
Itacitinib will be given at 200 mg orally daily from day -3 to day 90. Itacitinib will be given in conjunction with one of four different regimens for immunosuppression. These 4 regimens are listed in Table 2, Section 5.2 of the protocol. Itacitinib may continue beyond day +90 if there is GVHD. NOTE: If patient develops GVHD requiring treatment after all immune suppression, including itacitinib, is stopped on day +90, the itacitinib will not be restarted and the patient will be treated per standard of care.
Participants who did not reach PASI-90 after 12 weeks and were randomized to the Etanercept group. They received 50 mg Etanercept once per a week.
Yoga is an ancient discipline that emerged in India thousands of years ago, designed to bring balance and health to the physical, mental, emotional and spiritual dimensions of the individual.Due to its therapeutic effects, yoga can be considered as an alternative approach for those with rheumatic disease. Because of Covid-19, which has changed the world and the lifestyle of people, tele-yoga practice can be considered as an alternative instead of traditional face-to-face yoga classes. The use of online platforms provides a good environment for yoga training at home. The aim of this study is to investigate the effects of tele-yoga on functional level, disease activity, spinal mobility, balance, sleep quality, depression, mindfulness and quality of life in patients with ankylosing spondylitis.

60 AS patients who meet the inclusion criteria will be assigned to the tele-yoga or waiting list control group by the block randomization method. Patients in the tele-yoga group will participate in tele-yoga sessions with a maximum of 5 people in each group by video-conference method for 8 weeks, 3 days a week. Assessments will perform just before starting to study and after the 8-week tele-yoga program. Patients in the waiting list control group will be asked to continue their normal physical activities during the 8-week study, not to start a new exercise program, and to report any changes in the drug or dosage used. Control group's assessments will be performed when they are included in the study and at the end of 8 weeks. After these assessments, patients who wish will participate in the tele-yoga program.
PURPOSE: To obtain an antimetastatic factor capable of suppressing formation of cancer metastasis, comprising a protein substance having factor Xa inhibitory activity isolated from spittle or salivary gland of Haementeria ghilianii of leech. CONSTITUTION: Salivary gland of Haementeria ghilianii of leech is surgically removed and homogenized to give tissue homogenate, which is extracted with a solution of ammonium sulfate, acetone, etc. The extract is concentrated or dehydrated, chromatographed on DEAE cellulose, an anion exchange resin and a heparin/agarose resin, eluted with a linearly increasing salt gradient substance of sodium chloride to isolate a protein having antifactor Xa and anticoagulant activity. Then the factor Xa bonded to the chromatography resin is used and subjected to affinity chromatography to give an antimetastatic factor. The antimetastatic is effective for suppressing metastasis of melanoma, breast cancer, lung cancer and prostatic cancer. A daily dose is 0.01-2,000mg, preferably 1-200mg per kg weight.
An apparatus for creating a graphical representation of personalized healthcare information is provided. A data processing apparatus that has one or more processors is disclosed. Query component logic receives a request comprising patient identification information. Query execution logic, based on the patient information determines a first metric and one or more intervention metrics. The first metric represents a current health related metric for the patient, while the intervention metrics represent a predicted health related metric, assuming that the patient conforms to the intervention. A graphical representation of the two metrics is created.